Alon Ben-Noon Biography and Net Worth

CEO & Board Member of NeuroSense Therapeutics

Mr. Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics.

Prior to the establishment of NeuroSense, Alon founded MediCan Consulting, a successful consultancy firm, with clients from diversified biotech companies, including Mediwound, Chiasma, Teva, Sol-Gel, FutuRx, NeuroDerm and others. MediCan excelled at executing efficient, accurate, and innovative drug development programs for its clients.

Mr. Ben-Noon holds a MBA and BSc in Industrial Engineering, both from Ben-Gurion University.

What is Alon Ben-Noon's net worth?: The estimated net worth of Alon Ben-Noon is at least $29.74 million as of June 16th, 2026. Mr. Ben-Noon owns 4,534,233 shares of NeuroSense Therapeutics stock worth more than $29,744,568 as of September 14th. This net worth approximation does not reflect any other assets that Mr. Ben-Noon may own. Learn More about Alon Ben-Noon's net worth.
How do I contact Alon Ben-Noon?: The corporate mailing address for Mr. Ben-Noon and other NeuroSense Therapeutics executives is , , . NeuroSense Therapeutics can also be reached via phone at 972-9799-6183. Learn More on Alon Ben-Noon's contact information.
Has Alon Ben-Noon been buying or selling shares of NeuroSense Therapeutics?: Alon Ben-Noon has not been actively trading shares of NeuroSense Therapeutics over the course of the past ninety days. Most recently, on Tuesday, June 16th, Alon Ben-Noon bought 250,000 shares of NeuroSense Therapeutics stock. The stock was acquired at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,534,233 shares of the company's stock, valued at $3,627,386.40. Learn More on Alon Ben-Noon's trading history.
Who are NeuroSense Therapeutics' active insiders?: NeuroSense Therapeutics' insider roster includes Alon Ben-Noon (CEO & Board Member), and Or Eisenberg (Chief Financial Officer). Learn More on NeuroSense Therapeutics' active insiders.
Are insiders buying or selling shares of NeuroSense Therapeutics?: In the last twelve months, NeuroSense Therapeutics insiders bought shares 2 times. They purchased a total of 500,000 shares worth more than $400,000.00. The most recent insider tranaction occured on June, 16th when CEO Alon Ben-Noon bought 250,000 shares worth more than $200,000.00. Insiders at NeuroSense Therapeutics own 27.4% of the company. Learn More about insider trades at NeuroSense Therapeutics.
Information on this page was last updated on 6/16/2026.

Alon Ben-Noon Insider Trading History at NeuroSense Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/16/2026	Buy	250,000	$0.80	$200,000.00	4,534,233

Alon Ben-Noon Buying and Selling Activity at NeuroSense Therapeutics

NeuroSense Therapeutics Company Overview

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Today's Range

Now: $6.56

$5.60

$7.46

50 Day Range

MA: $0.52

$0.33

$0.73

2 Week Range

Now: $6.56

$5.00

$26.64

Volume

31,112 shs

Average Volume

12,092 shs

Market Capitalization

$248.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6